



June 18, 2020

SENT VIA ELECTRONIC MAIL

Dear Ryan White Part A and/or MAI-funded Subrecipient:

RE: Ryan White Part A Program Prescription Drug Formulary - Revised

Attached for your information and immediate distribution, please find the following **revised** documents:

- Miami-Dade County Ryan White Part A Program Prescription Drug Formulary in five (5) sorts: by therapeutic classification, pharmacologic classification, brand name, generic name, and drug code;
- Formulary Comments/Notations (Attachment A); no changes; reference only;
- Consumable Medical Supplies List (Attachment B); no changes; reference only.

NOTE: The revised Formulary, in all five (5) sorts, should be available on the Office of Management and Budget-Grants Coordination’s Ryan White Program (OMB) website (www.miamidade.gov/grants/ryan-white-program.asp#prescription), under the “Prescription Drug Services” link by Friday, June 26, 2020. The attached PDF documents may be shared with and disseminated to all interested parties.

The Medical Care Subcommittee recommended, and the Partnership approved the following changes to the Ryan White Part A Program Prescription Drug Formulary, **effective June 15, 2020:**

- Drug Formulary Updates/Additions, as follows:

Brand Name	Generic Name	RW Miami Pharm-Code	Action/Reason
Zetia®	ezetimibe	RX0820	This medication is on the Florida ADAP Formulary. It has been added to the Ryan White Part A/MAI Prescription Drug Formulary, effective June 15, 2020, a medication for high cholesterol.
Provera®	medroxyprogesterone acetate	RX1212	This medication is on the Florida ADAP Formulary. It has been added to the Ryan White Part A/MAI Prescription Drug Formulary, effective June 15, 2020.

As a reminder:

- The Miami-Dade County Ryan White Part A/MAI Prescription Drug Formulary is reviewed and revised periodically by the Miami-Dade HIV/AIDS Partnership and/or the Medical Care Subcommittee. It is imperative that all revisions to the Formulary, including, but not limited to, changes to the Comments/Notations page and Letters of Medical Necessity, when applicable, be carefully reviewed and understood by direct service staff and recipients of Ryan White Part A and MAI Program-funded medications.
- The Ryan White Program is the payer of last resort. If a client qualifies for and can access the medications through ADAP or any other payer source, the client must obtain the medications from those sources.
- All medications dispensed should be generic unless a generic version of the medication on the Ryan White Part A Program Prescription Drug Formulary is not available. However, Ryan White Part A/MAI Program-funded prescription drug subrecipients must use the most cost-effective product, either brand or generic, whichever is less expensive at the time of dispensing.

If further clarification is needed regarding the information in this letter or the recent changes, please contact Ana M. Nieto, Contracts Officer, or Carla Valle-Schwenk, Program Administrator, at (305) 375-4742. Thank you for your continued cooperation.

Sincerely,



for Daniel T. Wall
Assistant Director

Attachments

- c: Carla Valle-Schwenk, Program Administrator, OMB
Clarisol Nilsen, Fiscal Administrator, OMB
Bret F. Ballinger, President, Groupware Technologies, Inc.
Robert A. Ladner, PhD, President, BSR